Showing results (311-320 of 2,338) with videos related to
Sort By:
Pageof 234
Clinical Lung Cancer|June 14, 2011
A phase II study of higher dose weekly topotecan in relapsed small-cell lung cancerDavid R Spigel, F Anthony Greco, Howard A Burris, et al.Clinical Lung Cancer|June 14, 2011
Prognostic implications of parathyroid hormone-related protein in males and females with non--small-cell lung cancerPhilippe R Montgrain, Leonard J Deftos, Douglas Arenberg, et al.Clinical Lung Cancer|November 8, 2011
Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non-small-cell lung cancer: a meta-analysis of 13 randomized trialsFausto Petrelli, Karen Borgonovo, Mary Cabiddu, et al.Clinical Lung Cancer|November 8, 2011
Safety profile and tolerability of antiangiogenic agents in non-small-cell lung cancerShirish M GadgeelClinical Lung Cancer|March 20, 2012
Personalized medicine for non-small-cell lung cancer: implications of recent advances in tissue acquisition for molecular and histologic testingAndre L Moreira, Raymond H ThorntonClinical Lung Cancer|March 6, 2012
Mesothelin levels in urine are affected by glomerular leakage and tubular reabsorptionKevin Hollevoet, Marijn M Speeckaert, An-Sofie Decavele, et al.Clinical Lung Cancer|July 6, 2011
Long-term safety and tolerability of sorafenib in patients with advanced non-small-cell lung cancer: a case-based reviewAlex A Adjei, George R Blumenschein, Sumithra Mandrekar, et al.Clinical Lung Cancer|July 6, 2011
Analysis of lung cancer patients enrolled in CTEP (cancer therapy evaluation program)-sponsored phase I trialsShirish M Gadgeel, Percy Ivy, Wei Chen, et al.Clinical Lung Cancer|July 6, 2011
A phase I trial of bexarotene in combination with docetaxel in patients with advanced solid tumorsShakun M Malik, Brian Collins, Michael Pishvaian, et al.Clinical Lung Cancer|July 6, 2011
Downregulation of EMX2 is associated with clinical outcomes in lung adenocarcinoma patientsJunichi Okamoto, Johannes R Kratz, Tomomi Hirata, et al.Pageof 234